Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis.

@article{LopezOlivo2012RiskOM,
  title={Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis.},
  author={Maria A Lopez-Olivo and Jean H Tayar and Juan Antonio Mart{\'i}nez-L{\'o}pez and Eduardo Nicolas Pollono and Jose Polo Cueto and M Rosa Gonzales-Crespo and Stephanie Fulton and Maria E Suarez-Almazor},
  journal={JAMA},
  year={2012},
  volume={308 9},
  pages={898-908}
}
CONTEXT Concerns exist regarding the potential development of malignancies in patients with rheumatoid arthritis (RA) who are receiving biologic response modifiers (BRMs). OBJECTIVE To assess the risk of malignancy in patients with RA enrolled in randomized controlled trials (RCTs) of BRMs. DATA SOURCES Electronic databases, conference proceedings, and websites of regulatory agencies were searched for RCTs evaluating abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab… CONTINUE READING